Login to Your Account



Other News To Note


Monday, October 17, 2011
MediciNova Inc., of San Diego, will receive $2.5 million from Kissei Pharmaceutical Co. Ltd., of Tokyo, within 30 days for the development of MN-221, its drug for asthma or chronic obstructive pulmonary disease. MediciNova is developing the drug under a 2004 license agreement with Kissei

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription